AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7423172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study 30590600 — intervention group
Group type: EXPERIMENTAL
Intervention: Uninterrupted (UI) non-vitamin K antagonist oral anticoagulants (NOACs)
Number of subjects: 326
Study 30590600 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose skipped (SDS) NOACs
Number of subjects: 326
Study 30590600 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour skipped (24S) NOACs
Number of subjects: 326
Study 30590600 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (UI, SDS, 24S)
Number of subjects: 326
Study 28702717 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR) program
Number of subjects: 46
Study 28702717 — intervention group
Group type: COMPARATOR
Intervention: Video online support group
Number of subjects: 46
Study 25754330 — intervention group
Group type: COMPARATOR
Intervention: Tildrakizumab 3 mg/kg
Number of subjects: 29
Study 25754330 — intervention group
Group type: COMPARATOR
Intervention: Tildrakizumab 10 mg/kg
Number of subjects: 29
Study 25754330 — intervention group
Group type: COMPARATOR
Intervention: Tildrakizumab 3 mg/kg and 10 mg/kg (pooled)
Number of subjects: 29
Study 22848074 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (200 µg via ipsilateral peripheral vein about 3 min before puncture)
Number of subjects: 40
Study 22848074 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nitroglycerin)
Number of subjects: 40
Study 21878237 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehabilitation program (stationary cycling plus weight training)
Number of subjects: 95
Study 21878237 — intervention group
Group type: COMPARATOR
Intervention: Prehabilitation program (recommendation to increase walking and breathing exercises)
Number of subjects: 95
Study 21878237 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehabilitation (general)
Number of subjects: 95
Study 19167925 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg daily
Number of subjects: 3098
Study 19167925 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3098
Study 17391951 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐gamma‐1b (200 microg subcutaneously three times per week for 24 months)
Number of subjects: 14
Study 17391951 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (1mg orally per day for 24 months)
Number of subjects: 14
Study 14971971 — intervention group
Group type: EXPERIMENTAL
Intervention: Olympic lifting (OL) group
Number of subjects: 20
Study 14971971 — intervention group
Group type: COMPARATOR
Intervention: Power lifting (PL) group
Number of subjects: 20
Study 14971971 — intervention group
Group type: EXPERIMENTAL
Intervention: Both OL and PL groups
Number of subjects: 20
Study 11249725 — intervention group
Group type: EXPERIMENTAL
Intervention: BLP-25 vaccine with IL-2 in a liposomal delivery system
Number of subjects: 0
Study 11249725 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 9218922 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg
Number of subjects: 167
Study 9218922 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide 25 mg
Number of subjects: 167
Study 7957536 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexarelin 0.5 micrograms.kg‐1
Number of subjects: 12
Study 7957536 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexarelin 1 microgram.kg‐1
Number of subjects: 12
Study 7957536 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexarelin 2 micrograms.kg‐1
Number of subjects: 12
Study 7957536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3481508 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-amniotic PGF2 alpha 40 mg followed by oxytocin stimulation
Number of subjects: 28
Study 3481508 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical PGE2 1.0 mg in gel for 4 h followed by intra-amniotic PGF2 alpha 40 mg
Number of subjects: 28
Study 3481508 — intervention group
Group type: COMPARATOR
Intervention: Intracervical PGE2 1.0 mg in gel
Number of subjects: 28
Study 30142427 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (regular exercise)
Number of subjects: 154
Study 30142427 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 154
Study 26850877 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) dexmedetomidine (1.0 μg/kg)
Number of subjects: 240
Study 26850877 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal (IN) dexmedetomidine (1.5 μg/kg)
Number of subjects: 240
Study 26850877 — intervention group
Group type: COMPARATOR
Intervention: Local anesthesia
Number of subjects: 240
Study 25511923 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine maintenance therapy
Number of subjects: 0
Study 25511923 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib maintenance therapy
Number of subjects: 0
Study 25511923 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 0
Study 23377520 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA with occlusion (ALA+OCC)
Number of subjects: 70
Study 23377520 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoccluded ALA
Number of subjects: 70
Study 23377520 — intervention group
Group type: COMPARATOR
Intervention: VEH with occlusion (VEH+OCC)
Number of subjects: 70
Study 23377520 — intervention group
Group type: COMPARATOR
Intervention: Nonoccluded VEH
Number of subjects: 70
Study 20375028 — intervention group
Group type: EXPERIMENTAL
Intervention: Community care (n = 33)
Number of subjects: 65
Study 20375028 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 32)
Number of subjects: 65
Study 18184543 — intervention group
Group type: EXPERIMENTAL
Intervention: Western medicine (WM) therapy including voltaren extended action tablet, methotrexate, and sulfasalazine
Number of subjects: 413
Study 18184543 — intervention group
Group type: COMPARATOR
Intervention: Traditional Chinese medicine (CM) therapy including glucosidorum Tripterygll totorum tablet and Yishen Juanbi Tablet
Number of subjects: 413
Study 18184543 — intervention group
Group type: EXPERIMENTAL
Intervention: Western medicine (WM) therapy
Number of subjects: 413
Study 15250433 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (maximum tolerated dose, 75 mg in most cases)
Number of subjects: 30
Study 15250433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 15250433 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 30
Study 12566887 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% tropicamide instilled in treated eyes after PRK
Number of subjects: 28
Study 12566887 — intervention group
Group type: COMPARATOR
Intervention: Untreated eyes (control)
Number of subjects: 28
Study 12566887 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% tropicamide in treated eyes with myopia above 6 diopters
Number of subjects: 28
Study 12566887 — intervention group
Group type: COMPARATOR
Intervention: Untreated eyes with myopia above 6 diopters (control)
Number of subjects: 28
Study 12566887 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% tropicamide in treated eyes with cornea thinner than 540 micrometers
Number of subjects: 28
Study 12566887 — intervention group
Group type: COMPARATOR
Intervention: Untreated eyes with cornea thinner than 540 micrometers (control)
Number of subjects: 28
Study 9717594 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 IU oxytocin i.v. and 2 ml saline imy
Number of subjects: 40
Study 9717594 — intervention group
Group type: COMPARATOR
Intervention: 20 IU oxytocin into the myometrium and 0.5 ml saline i.v.
Number of subjects: 40
Study 9717594 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (i.v. and imy oxytocin)
Number of subjects: 40
Study 8628581 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (mean dose: 32 mg)
Number of subjects: 12
Study 8628581 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil (mean dose: 3075 micrograms)
Number of subjects: 12
Study 8628581 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 12
Study 2501394 — intervention group
Group type: EXPERIMENTAL
Intervention: Mupirocin (Bactroban) ointment applied twice daily for 7 days
Number of subjects: 413
Study 2501394 — intervention group
Group type: COMPARATOR
Intervention: Sodium fusidate (Fucidin) ointment applied thrice daily for 7 days
Number of subjects: 413
Study 2501394 — intervention group
Group type: EXPERIMENTAL
Intervention: Mupirocin
Number of subjects: 413
Study 2501394 — intervention group
Group type: COMPARATOR
Intervention: Sodium fusidate
Number of subjects: 413
Study 353089 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg phenobarbital plus 8 mg belladonna (P & B)
Number of subjects: 16
Study 353089 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31676719 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based care from patient-nominated lay people trained to deliver intramuscular streptomycin.
Number of subjects: 204
Study 31676719 — intervention group
Group type: COMPARATOR
Intervention: Standard care (hospital-based management) for 2 months of streptomycin.
Number of subjects: 204
Study 31676719 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based management.
Number of subjects: 204
Study 31676719 — intervention group
Group type: COMPARATOR
Intervention: Hospital-based management.
Number of subjects: 204
Study 31676719 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based care and hospital-based care.
Number of subjects: 204
Study 31436494 — intervention group
Group type: EXPERIMENTAL
Intervention: FBT+egg
Number of subjects: 50
Study 31436494 — intervention group
Group type: COMPARATOR
Intervention: FBT+cereal
Number of subjects: 50
Study 28835651 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS
Number of subjects: 19
Study 28835651 — intervention group
Group type: COMPARATOR
Intervention: Sham-tDCS
Number of subjects: 19
Study 24706006 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (initial treatment), followed by either sulfasalazine+hydroxychloroquine or infliximab for non-responders.
Number of subjects: 311
Study 24706006 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smoking status
Number of subjects: 311
Study 24706006 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline erosions
Number of subjects: 311
Study 24706006 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythrocyte sedimentation rate
Number of subjects: 311
Study 24706006 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein
Number of subjects: 311
Study 23220209 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Number of subjects: 156
Study 23220209 — intervention group
Group type: COMPARATOR
Intervention: Nevirapine
Number of subjects: 156
Study 21785396 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 0.25 mg/g cream in the morning and tacalcitol 4 µg/g ointment in the evening
Number of subjects: 20
Study 21785396 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriol 50 µg/g plus betamethasone dipropionate 0.5 mg/g ointment once daily
Number of subjects: 20
Study 19346879 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam plus ceftazidime (PIPC/TAZ+CAZ)
Number of subjects: 134
Study 19346879 — intervention group
Group type: COMPARATOR
Intervention: Sulbactam/ampicillin plus aztreonam (SBT/ABPC+AZT)
Number of subjects: 134
Study 16699359 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy (20 minutes)
Number of subjects: 86
Study 16699359 — intervention group
Group type: COMPARATOR
Intervention: Control (20 minutes of quiet, uninterrupted rest)
Number of subjects: 86
Study 16699359 — intervention group
Group type: COMPARATOR
Intervention: Music therapy and Control
Number of subjects: 86
Study 15567701 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy derivative PD control approach for insulin infusion
Number of subjects: 0
Study 15567701 — intervention group
Group type: EXPERIMENTAL
Intervention: Modelled insulin infused
Number of subjects: 0
Study 15567701 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy derivative PD control approach
Number of subjects: 0
Study 11699800 — intervention group
Group type: EXPERIMENTAL
Intervention: Adderall
Number of subjects: 35
Study 11699800 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release dextroamphetamine sulfate
Number of subjects: 35
Study 11699800 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine Spansules
Number of subjects: 35
Study 11699800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 11699800 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release amphetamines
Number of subjects: 35
Study 9085124 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms of 105AD7
Number of subjects: 135
Study 9085124 — intervention group
Group type: COMPARATOR
Intervention: 200 micrograms of 105AD7
Number of subjects: 135
Study 7624642 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional fractionated radiation therapy (20 and 45 Gy delivered in 10 and 15 fractions)
Number of subjects: 15
Study 7624642 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional fractionated radiation therapy
Number of subjects: 15
Study 3688637 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (Indocin SR 75 mg every 12 h for 5 days)
Number of subjects: 14
Study 3688637 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 3688637 — intervention group
Group type: COMPARATOR
Intervention: No drug
Number of subjects: 14
Study 28401441 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient multicomponent occupational rehabilitation (4+4 days) including Acceptance and Commitment Therapy (ACT), physical training, and work-related problem-solving.
Number of subjects: 168
Study 28401441 — intervention group
Group type: COMPARATOR
Intervention: Outpatient rehabilitation (6 sessions during 6 weeks) primarily consisting of ACT.
Number of subjects: 168
Study 28401441 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient multicomponent occupational rehabilitation (4+4 days).
Number of subjects: 168
Study 28401441 — intervention group
Group type: COMPARATOR
Intervention: Outpatient rehabilitation (6 sessions during 6 weeks).
Number of subjects: 168
Study 27927174 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex mental health intervention for carers and case managers
Number of subjects: 176
Study 24655702 — intervention group
Group type: EXPERIMENTAL
Intervention: Clevidipine
Number of subjects: 104
Study 24655702 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SOC)
Number of subjects: 104
Study 24138805 — intervention group
Group type: EXPERIMENTAL
Intervention: BBOFT+ intervention
Number of subjects: 51
Study 24138805 — intervention group
Group type: EXPERIMENTAL
Intervention: E-health4Uth Healthy toddler intervention
Number of subjects: 51
Study 24138805 — intervention group
Group type: COMPARATOR
Intervention: Control group (care as usual)
Number of subjects: 51
Study 20598577 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 0
Study 20598577 — intervention group
Group type: EXPERIMENTAL
Intervention: Alphacalcidol
Number of subjects: 0
Study 17940146 — intervention group
Group type: EXPERIMENTAL
Intervention: Open kinetic chain (OKC) quadriceps strengthening
Number of subjects: 42
Study 17940146 — intervention group
Group type: COMPARATOR
Intervention: Closed kinetic chain (CKC) quadriceps strengthening
Number of subjects: 42
Study 17940146 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CKC and OKC)
Number of subjects: 42
Study 16521015 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-made radiolucent modular splint for stress radiographs
Number of subjects: 11
Study 16521015 — intervention group
Group type: COMPARATOR
Intervention: Manual positioning for stress radiographs
Number of subjects: 11
Study 12740743 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplement
Number of subjects: 22
Study 12740743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 10826254 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term exercise intervention
Number of subjects: 0
Study 10826254 — intervention group
Group type: COMPARATOR
Intervention: Long-term exercise intervention
Number of subjects: 0
Study 8775366 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium supplementation (200 micrograms.d‐1)
Number of subjects: 16
Study 8775366 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive exercise training program (12 weeks, 3 times per week, 2 sets of 8-10 repetitions at 90% of 1 repetition maximum)
Number of subjects: 16
Study 8775366 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (no chromium supplementation)
Number of subjects: 16
Study 1478163 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor 250 mg
Number of subjects: 80
Study 1478163 — intervention group
Group type: COMPARATOR
Intervention: Macrocrystalline nitrofurantoin 50 mg
Number of subjects: 80
Study 3958952 — intervention group
Group type: EXPERIMENTAL
Intervention: Amvisc
Number of subjects: 0
Study 3958952 — intervention group
Group type: COMPARATOR
Intervention: Healon
Number of subjects: 0
Study 29217156 — intervention group
Group type: EXPERIMENTAL
Intervention: Air-Q®
Number of subjects: 33
Study 29217156 — intervention group
Group type: COMPARATOR
Intervention: LMA Fastrach™
Number of subjects: 33
Study 27210830 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral engagement intervention by phone
Number of subjects: 0
Study 25182501 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck coordination exercise
Number of subjects: 108
Study 25182501 — intervention group
Group type: COMPARATOR
Intervention: Strength training
Number of subjects: 108
Study 25182501 — intervention group
Group type: COMPARATOR
Intervention: Massage
Number of subjects: 108
Study 22877506 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic platelet transfusion strategy (transfusion when bleeding occurred)
Number of subjects: 391
Study 22877506 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic platelet transfusion strategy (transfusion when platelet counts were 10×10(9) per L or lower)
Number of subjects: 391
Study 22877506 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic strategy in patients with acute myeloid leukaemia
Number of subjects: 391
Study 22877506 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic strategy in patients who had autologous transplantation
Number of subjects: 391
Study 22877506 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic strategy
Number of subjects: 391
Study 22877506 — intervention group
Group type: EXPERIMENTAL
Intervention: Both strategies
Number of subjects: 391
Study 20451898 — intervention group
Group type: EXPERIMENTAL
Intervention: Anisometropic amblyopia (with or without strabismus)
Number of subjects: 2635
Study 20451898 — intervention group
Group type: EXPERIMENTAL
Intervention: Strabismic‐only amblyopia
Number of subjects: 2635
Study 18271963 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza season defined by a three-week moving average of positive influenza isolates at least 5%
Number of subjects: 0
Study 18271963 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza season defined by a three-week moving average of positive influenza isolates at least 10%
Number of subjects: 0
Study 18271963 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza season defined by first and last positive influenza isolate identified
Number of subjects: 0
Study 18271963 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza season defined by 5% of total number of positive isolates for the season obtained
Number of subjects: 0
Study 18416847 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended sigh (eSigh)
Number of subjects: 19
Study 18416847 — intervention group
Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 19
Study 15143453 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon, ribavirin, and amantadin
Number of subjects: 74
Study 15143453 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 11748098 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin therapy
Number of subjects: 1003
Study 11748098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1003
Study 8988938 — intervention group
Group type: EXPERIMENTAL
Intervention: Special intervention group with dietary goals of reduced saturated fat and cholesterol, and increased polyunsaturated fat; total fat intake decreased for energy control.
Number of subjects: 0
Study 8988938 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day food records scoring and subjective evaluation by nutritionists.
Number of subjects: 0
Study 8214804 — intervention group
Group type: EXPERIMENTAL
Intervention: Large particle heated water vapor at 43 degrees C for 20 minutes (particle size 4 to 8 microns)
Number of subjects: 30
Study 8214804 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular water vapor at 41 degrees C for 20 minutes (vapor phase)
Number of subjects: 30
Study 8214804 — intervention group
Group type: COMPARATOR
Intervention: Nasal irrigation
Number of subjects: 30
Study 3307717 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 1% ALO 2145 (p‐aminoclonidine hydrochloride)
Number of subjects: 21
Study 3307717 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 31201057 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated reminder to recommend the 2nd or 3rd dose of HPV vaccine
Number of subjects: 1285
Study 31201057 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (control group)
Number of subjects: 1285
Study 28454800 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive 37‐hour educational program for preschool children over 4 months
Number of subjects: 1200
Study 28454800 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual‐focused or peer‐to‐peer based intervention for adults
Number of subjects: 1200
Study 26054139 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture group (abdominal acupuncture at specific points)
Number of subjects: 60
Study 26054139 — intervention group
Group type: COMPARATOR
Intervention: Medication group (basic treatment combined with oral administration of regular antidiabetics)
Number of subjects: 60
Study 26054139 — intervention group
Group type: COMPARATOR
Intervention: Comparison between acupuncture and medication groups
Number of subjects: 60
Study 23537391 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 100